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Background. Cardiac allograft vasculopathy (CAV) is a major cause of graft loss and death after heart transplantation. Currently,
no diagnostic methods are available during the early post-transplant period to accurately identify patients at risk of CAV. We
hypothesized that PBMC gene expression proﬁles (GEP) can identify patients at risk of CAV. Methods. We retrospectively analyzed
a limited set of whole-genome PBMC microarrays from 10 post-transplant patients who did (n = 3) or did not (n = 7) develop
advanced grade CAV during their long-term follow-up. We used signiﬁcance analysis of microarrays to identify diﬀerentially
expressed genes and High-Throughput GoMiner to assess gene ontology (GO) categories. We corroborated our ﬁndings by
retrospective analysis of PBMC real-time PCR data from 33 patients. Results. Over 300 genes were diﬀerentially expressed (FDR <
5%), and 18 GO-categories including “macrophage activation”, “Interleukin-6 pathway”, “NF-KappaB cascade”, and “response to
virus” were enriched by these genes (FDR < 5%). Out of 8 transcripts available for RT-PCR analysis, we conﬁrmed 6 transcripts
(75.0%) including FPRL1, S100A9, CXCL10, PRO1073, and MMP9 (P<. 05). Conclusion. Our pilot data suggest that GEP of
PBMC may become a valuable tool in the evaluation of patients at risk of CAV. Larger prospectively designed studies are needed to
corroborate our hypothesis.
1.Introduction
Cardiac allograft vasculopathy (CAV) is a major cause of
graft loss and death after heart transplantation (HTx).
Identiﬁcation of surrogate makers for late cardiac allograft
survival has been of major interest to improve long-term
outcomes of HTx [1]. After HTx, alloantigens (includ-
ing molecules from donor endothelium) are presented
by antigen-presenting cells to the recipient’s T-cells, often
generating a diﬀerentiated inﬂammatory response. That
response includes T-cells, B-cells, and a coordinated pattern
of cytokine release. Cells of innate immunity (monocyte-
derived macrophages) are also involved [1]. Non-antigen-
speciﬁc perioperative events including microvascular insults
may play pivotal roles related to subsequent development
of CAV, probably related to ischemia reperfusion injury,
advanced donor age, hyperlipidemia, depletion of arte-
riolar tissue plasminogen activator factor and systemic2 Journal of Transplantation
inﬂammation [1–8]. The inﬂammatory response culminates
in migration of mononuclear cells through the coronary
vascular endothelium and phenotypic switching of medial
smooth muscle cells mediated by generation of growth-
promoting cytokines. Those processes contribute to chronic
damage of the coronary arteries of the transplanted heart.
Theresultisthedevelopmentofadiﬀuse,obliterativeformof
vasculopathy characterized by production of a “neointima”
rich in vascular smooth muscle cells and extracellular matrix
[9, 10]. After the ﬁrst year post-transplantation, 30% to 50%
of patients have some evidence of CAV and after 5 years
CAV is one of the leading causes of death with <50% 1-year
survival rate in those with extended disease [11, 12].
Limited interventions have been shown to prevent, delay,
or reverse CAV. While no deﬁnite well-validated surrogate
marker for late cardiac allograft outcome is available, early
detection of CAV represents the key strategy as an eﬀective
surrogate [1]. Early identiﬁcation of CAV became possible
with the introduction of intravascular ultrasound (IVUS)
[13], but the technique is invasive, it is usually not initiated
until at least one year post-transplantation, is expensive, and
requires the use of nephrotoxic contrast agents. Noninvasive
tests, including stress perfusion, dobutamine echocardiogra-
phy, ultrafast tomography, and MRI have not proven to be
suﬃciently sensitive or speciﬁc to detect early stages of the
disease [14, 15]. Therefore, there are clear needs to explore
and develop new options for the early evaluation of patients
at risk of CAV.
Recently, gene expression proﬁles of peripheral blood
mononuclear cells (PBMC) were used to identify patients
with [16, 17]o rw i t h o u tm o d e r a t ea n ds e v e r ea c u t ec e l l u l a r
cardiac allograft rejection [18] and patients at risk of
antibody-mediated rejection [19].
Since the peripheral recirculation of recipient leukocytes
after allo-endothelial-cell contact in the allograft may carry
information about immune activation conducive to chronic
rejectiondevelopment,wehypothesizedthatgeneexpression
proﬁles of PBMC obtained early after HTx carry molecular
signaturesthatcorrelatewiththefuturedevelopmentofCAV.
2.MaterialsandMethods
2.1. Patients, Samples, and Microarrays. We analyzed a
limited set of 41,000 gene expression proﬁles (whole-
genome Microarray, Agilent Technologies, Wilmington, DE)
obtained from patients included in a large multicenter study
(Cardiac Allograft Rejection Gene Expression Observational
[CARGO] study) that used microarrays to identify PBMC
gene signatures of acute cellular cardiac allograft rejec-
tion [18]. Columbia University Medical Center (CUMC)
contributed 121 patients. Out of the Columbia University
cohort, independent whole genome PBMC samples from 10
patients were available. The study protocol was approved
by the Institutional Review Board (IRB) of CUMC. PBMC
were isolated from eight mL of venous blood using density
gradient centrifugation (CPT, Becton-Dickinson, Franklin
Lakes, NJ). Samples were frozen in lysis buﬀer (RLT, Qiagen,
Valencia, CA) within 2h of phlebotomy. Total RNA was
isolated from each sample (RNeasy, Qiagen, Valencia, CA).
Whole genome gene expression proﬁling was performed on
two-color Whole Human Genome 60-mer Oligo Microar-
rays (Agilent Technologies, Santa Clara, CA), which contain
41,000+ unique transcripts. After the hybridization, data
were extracted and Lowess normalized expression ﬁles were
generously provided by the CARGO study sponsor (XDx
Inc., Brisbane, CA). Filtering was done against background
and only those probes with more than 1.5-fold change were
retained. Probes mapping to the same gene transcript were
not averaged.
2.2. Cardiac Allograft Vasculopathy. Patients were eligible
for the study if they were evaluated with angiography
during their post-transplant course. CAV was deﬁned as any
evidence of disease in the angiography as evaluated by one
of three expert interventional cardiologists who specialized
in heart transplantation care at the Center for Interventional
Vascular Therapy at Columbia University. Angiograms were
classiﬁed as normal (no evidence of vasculopathy), mild
(any grade of angiographic luminal stenosis less than 50%),
moderate (any angiographic luminal stenosis greater than
50% in a main vessel or two secondary branches), and severe
(more than 50% in the left main or two main vessels).
Patients with moderate or severe CAV were considered
“advanced”.
2.3. Statistical Analysis. Quantitative and qualitative clinical
variables were compared by the Mann Whitney U-test,
Chi-Square test, or Fischer-exact when appropriate using
SPSS 11.5.1 (SPSS Inc., 2002). A P-value <.05 was regarded
as signiﬁcant. Gene expression of samples obtained from
patients with advanced CAV was compared against those
with normal or mild disease using independent, unpaired
t-test, and Benjamini-Hochberg correction for multiple
comparisons to estimate a false discovery rate (FDR) as
implemented in signiﬁcance analysis of microarrays (SAM)
[20] after 1.5-fold change ﬁltering. Genes were retained
for further analyses if FDR < 5%. Molecular function and
biological processes associated with individual signiﬁcant
genes were determined using PANTHER (Protein ANalysis
THrough Evolutionary Relationships) Classiﬁcation System
(http://www.pantherdb.org), a unique resource that classiﬁes
genes by their functions, using published scientiﬁc exper-
imental evidence and evolutionary relationships to predict
functionevenintheabsenceofdirectexperimentalevidence.
Quantitative, real-time PCR cycle thresholds (CT) for each
group were compared with the Mann Whitney U-test. P-
value <.05 was considered signiﬁcant.
2.4. Hierarchical Clustering. Gene expression data were cor-
related and visualized in clustered heat maps [21] using the
Genesis web interface ((http://carmaweb.genome.tugraz.at/
genesis/index2.html), Institute for Genomics and Bioinfor-
matics, Graz University of Technology, Graz, Austria). Top
1 0 0g e n e sa n dm i c r o a r r a ys a m p l e sa sw e l la sd i ﬀerentially
enriched GO categories and genes were clustered on the basis
of co-occurrence of the diﬀerentially expressed genes using
the Pearson metric and average linkage.Journal of Transplantation 3
Table 1: Baseline clinical characteristics. Baseline Clinical Characteristics Comparing Microarray and PCR Study Populations.
(a)
Microarray study (N = 10) PCR study (N = 33)
Variable Normal or
mild (N = 7)
Advanced CAV
(N = 3) P-value Normal or
mild (N = 28)
Advanced CAV
(N = 5) P-value
Time after HTx (days) 232 (81–298) 42 (41–96) .067 81 (7–171) 55 (41–167) .643
Follow-up time (years) 5.3( 4 .8–5.8) 5.6( 5 .4–5.7) .138 5.5( 4 .6–6.2) 5.7( 5 .1–5.8) .315
Male gender recipient 6 (85.7%) 3 (100%) 1 21 (75.0%) 4 (80%) 1
Male gender donor 6 (85.7%) 2 (66.7%) 1 20 (71.4%) 3 (60%) .627
Caucasian recipient 5 (71.4%) 3 (100%) .585 21 (63.6%) 5 (100%) .903
Caucasian donor 7 (100%) 1 (33%) .67 17 (60.7%) 2 (40%) .685
Recipient age 55.6 ± 8.24 8 .5 ±13.5 .383 52.6 ±105 61.4 ±8 .173
Donor age 31.7 ±11.74 4 .1 ±7.9 .183 32.8 ±13.04 1 .5 ±13.7 .226
ICM recipient 5 (71.4%) 1 (33.3%) .11 14 (50%) 4 (80%) .267
LVAD 3 (42.9%) 2 (66.7%) 1 7 (21.2%) 2 (40%) .597
Recipient CMV (+) 2 (28.6%) 0 (0.00%) .53 11 (33.3%) 2 (40%) .347
Donor CMV (+) 3 (42.9%) 2 (40.0%) .7 14 (50%) 4 (80%) .445
Ischemic time (Min) 188.7 ± 65.1 138 ±36.6 .229 183.9 ±49.2 156 ±7 .208
Daclizumab induction 7 (100%) 3 (100%) — 24 (85.7%) 4 (80%)
Prednisone 7 (100%) 3 (100%) — 28 (100%) 5 (100%) —
Prednisone dose 8.71 ± 7.81 3 .3 ±2.9 .296 16.3 ±10.21 3 .0 ±4.5 .359
Maintenance Regimen 1 .295
Cyclosporine 6 (85.7%) 3 (100%) 24 (85.7%) 4 (80%)
Tacrolimus 1 (14.3%) 0 (0.0%) 3 (10.7%) 0 (0%)
Sirolimus 0 (0.0%) 0 (0.0%) 1 (3.6%) 1 (20%)
Cyclosporine levels (ng/ml) 437.0 ±489 225.3 ±26 .655 312.5 ±226 229.25 ±22 .212
Tacrolimus levels (ng/ml) 8.5 ±0.2— — 1 1 .7 ±2.5— —
Sirolimus levels (ng/ml) — — — 6 5.6 —
Mycophenolate 6 (85.7%) 3 (100%) 1 24 (85.7%) 5 (100%) 1
Azathioprine 0 (0.0%) 0 (0.0%) — 0 (0.0%) 0 (0.0%) —
Simvastatin 1 (14%) 1 (33%) 1.00 2 (7%) 0 (0%) 1.00
Cellular rejection (ISHLT) .161 .78
0R 4 (57.1%) 2 (66.7%) 24 (85.7%) 4 (80%)
1R 3 (42.9%) 0 (0.0%) 4 (14.3%) 1 (20%)
2R 0 (0.0%) 1 (33.3%) 0 (0%) 0 (0%)
New episodes of rejection
1R/1B 0 (0–1) 0 (0–0) .513 0 (0–4) 0 (0–3) .688
2R 1 (0–1) 1 (0–1) .789 0 (0–2) 0 (0–1) .375
2R/3A 0 (0–1) 0 (0–0) .513 0 (0–2) 0 (0–3) .898
HTx: heart transplant; LVAD: left ventricular assist device; RT-PCR: real-time polymerase chain reaction.
(b)
Normal or mild Advanced CAV Microarray versus PCR (N = 43)
Variable Microarray
(N = 7)
RT-PCR
(N = 28) P-value Microarray
(N = 3)
RT-PCR
(N = 5) P-value Microarray
(N = 10)
RT-PCR
(N = 33) P-value
Time after HTx
(days) 232 (81–298) 81 (7–171) .002 42 (41–96) 55 (41–167) .571 154.5 ±99.57 6 .4 ±47.5 .037
Follow-up time
(years) 5.3( 4 .8–5.8) 5.5( 4 .6–6.2) .433 5.6( 5 .4–5.7) 5.7( 5 .1–5.8) .451 5.3 ±0.35 .4 ±0.4 .5834 Journal of Transplantation
(b) Continued.
Normal or mild Advanced CAV Microarray versus PCR (N = 43)
Variable Microarray
(N = 7)
RT-PCR
(N = 28) P-value Microarray
(N = 3)
RT-PCR
(N = 5) P-value Microarray
(N = 10)
RT-PCR
(N = 33) P-value
Male gender
recipient 6( 8 5 .7%) 21 (75%) 1 3 (100%) 4 (80%) 1 9 (90%) 25 (75.8%) .659
Male gender
donor 6( 8 5 .7%) 20 (21.4%) .648 2 (66.7%) 3 (60%) 1 8 (80%) 23 (69.7%) .698
Caucasian
recipient 5( 7 1 .4%) 21 (75%) .781 3 (100%) 5 (100%) 8 (80%) 26 (78.8%) .823
Caucasian donor 7 (100%) 17 (60.7) .26 1 (33.3%) 2 (40%) .641 8 (80%) 19 (57.6%) .433
Recipient age 55.6 ± 8.25 2 .6 ±10.5 .43 48.6 ±13.56 1 .4 ±8.0 .393 53.5 ±9.85 3 .9 ±10.5 .916
Donor age 31.7 ±11.63 2 .8 ±13.0 .888 44.1 ±7.94 1 .55 ±13.613 5 .4 ±11.83 4 .1 ±13.3 .559
ICM recipient 5 (71.4%) 14 (50%) .941 1 (33.3%) 4 (80%) .293 6 (60%) 18 (54.5%) .668
LVAD 3 (42.9%) 7 (25%) .31 2 (66.7%) 2 (40%) 1 5 (50%) 9 (27.3%) .252
Recipient CMV
(+) 2( 2 8 .6%) 11 (39.3%) .523 0 (0.0%) 2 (40%) .449 2 (20%) 13 (39.4%) .291
Donor CMV (+) 3 (42.9%) 14 (50%) .822 2 (66.7%) 4 (80%) 1 5 (50%) 18 (54.5%) .904
Ischemic times
(Min)
188.75 ±
65.13 183.9 ±49.2 .706 138.0 ±36.6 156.0 ±7 .786 167 ±57.5 178.7 ±45.6 .495
Daclizumab
induction 7 (100%) 24 (85.7%) .562 3 (100%) 4 (80%) 10 (100%) 28 (84.8%) .32
Prednisone 7 (100%) 28 (100%) — 3 (100%) 5 (100%) 10 (100%) 33 (100%)
Prednisone dose 8.7 ±7.81 6 .3 ±10.2 .015 13.3 ±2.91 3 .0 ±4.5 .845 10.1 ±6.81 5 .79 ±9.5 .041
Maintenance
regimen .85 .4 .727
Cyclosporine 6 (85.7%) 24 (85.7%) 3 (100%) 4 (80%) 9 (90%) 28 (84.8%)
Tacrolimus 1 (14.3%) 3 (10.7%) 0 (0.0%) 0 (0.0%) 1 (10%) 3 (9.1%)
Sirolimus 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (20%) 0 (0.0%) 2 (6.1%)
Cyclosporine
levels (ng/ml) 437.0±489.4 312.5 ±226 .686 225.3 ±26.6 229.25 ±22.6 1 357.6 ±386 300.6 ±211 .47
Tacrolimus levels
(ng/ml) 8.5 ±0.21 1 .7 ±2.5 .083 — — 8.5 ±0.21 1 .7 ±2.5 .083
Sirolimus levels
(ng/ml) —6 —5 . 6 — 1 1 .7 ±2.5—
Mycophenolate 6 (85.7%) 24 (85.7%) 1 3 (100%) 5 (100%) 9 (90%) 28 (84.8%) 1
Azathioprine 0 (0.0%) 0 (0.0%) — 0 (0.0%) 0 (0.0%) — 0 (0.0%) 0 (0.0%) —
Simvastatin 1 (14%) 2 (7%) .499 1 (33%) 0 (0%) .375 2 (20%) 2 (6%) .226
Cellular rejection
(ISHLT) .123 .315 .127
0R 4 (57.1%) 24 (85.7%) 2 (66.7%) 4 (80%) 6 (60%) 28 (84.8%)
1R 3 (42.9%) 4 (14.3%) 0 (0.0%) 1 (20%) 3 (30%) 5 (15.1%)
2R 0 (0.0%) 0 (0.0%) 1 (33.3%) 0 (0.0%) 1 (10%) 0 (0.0%)
New Episodes of
Rejection
1R/1B 0 (0–1) 0 (0–4) .3 0 (0–0) 0 (0–3) .439 0 (0–1) 0 (0–4) .17
2R 1 (0–1) 0 (0–2) .59 1 (0–1) 0 (0–1) .217 1 (0–1) 0 (0–2) .32
2R/3A 0 (0–1) 0 (0–2) .4 0 (0–0) 0 (0–3) .439 0 (0–1) 0 (0–3) .235
HTx: heart transplant; LVAD: left ventricular assist device; RT-PCR: real time polymerase chain reaction.Journal of Transplantation 5
2.5. Gene Ontology Analysis. We used High-Throughput
GoMiner (HTGM) [22]( http://discover.nci.nih.gov/)t o
analyze the list of interesting genes in the context of gene
ontology (GO) categories [23]. HTGM analyzes data from
all microarrays in a study, provides diagnostics for data
interpretation and visualization tools in terms of specialized
clustered “heat maps” (also called clustered image maps,
CIMs)[21].Normally,theinputtoHTGMconsistsofatotal-
genes ﬁle (representing the entire Microarray or a randomly
generated whole genome seed) and a changed-genes ﬁle
(representing the genes with altered expression) relevant
to the study purpose. The output generated by HTGM
includes a summary of the results, a matrix whose rows are
categories and whose columns are names of changed gene
forhierarchicalclusteringofexperimentsandcategories,and
a statistical summary for each category including one-sided
Fisher exact P-value and an FDR. Hierarchical clustering of
enriched categories and changed genes allows determining
which categories achieved statistical signiﬁcance by virtue of
containing essentially the same set of changed genes.
3. Results
3.1. Patient Demographics. The baseline characteristics of
the study population, including mean age, gender, race,
diagnosis, mean cold ischemia time, induction strategy,
antirejection prophylaxis, median follow-up time at the
time that the microarrays were obtained, median follow-
up time till the diagnosis of CAV, simvastatin use, and
median number of rejection episodes (i.e., 1R/1B, 2R,
and 2R/3A) requiring augmented immunosuppression are
depicted in Tables 1(a) and 1(b) for the overall population
and by study subgroups and sample method. All baseline
clinical characteristics were comparable across groups in
both microarray and PCR studies. Although the diﬀerence
in timing of blood sample post-HTx between advanced
CAV and normal/mild CAV groups in the microarray study
population approached the deﬁned level of signiﬁcance (P =
.06) but this diﬀerence was not signiﬁcant in the PCR study
population.
3.2. Microarray Analysis. Out of 10 patients who were
studied with microarrays, 3 (30%) had advanced CAV while
7 (70%) had angiograms consistent with either absence of
disease (n = 3, 30%) or mild disease (n = 4, 40%). Compar-
ison of study samples for each study group is summarized
in Table 1(a). One sample that had 2R (moderate) cellular
cardiac allograft rejection was retained given the limited
small Microarray dataset.
3.3. RT-PCR Analysis. There were 64 Quantitative, 253 tran-
script, Real-Time PCR samples available from our Center,
obtained from 43 patients during the CARGO study [18].
Nine samples from 9 patients associated with ISHLT grade
3A/2R rejection and 1 sample without rejection grading
information were excluded. Out of the remaining samples,
3 samples had no angiographic information, 1 sample had
aneurismatic disease diagnosed at year 1 without further
information in subsequent years, and 18 samples from
13 patients were repeated. For repeated samples, we choose
the one closest to the median time from the transplant
surgery to the date that all samples were obtained. Therefore,
we retained 33 samples obtained from 33 patients for this
analysis. Twenty-eight PCR samples (85%) belonged to
patients from the normal (n = 20) or mild disease (n =
8) group, and 5 samples (15%) belonged to patients with
advanced CAV.
3.4. Gene Expression Proﬁles. Between-group comparisons
identiﬁed 316 transcripts from 291 unique genes diﬀeren-
tially expressed with FDR ≤ 5%: 182 transcripts (170 genes)
were up-regulated and 134 transcripts (123 genes) were
down-regulated. Top up- and down-regulated genes and
their functions are depicted in (Table 2)a n dac l u s t e r e dh e a t
map of top 100 up- and down-regulated genes is shown in
(Figure 1). A complete list of genes with their respective fold
changes and false discovery rates is provided as supplemen-
tary material available online at doi:10.1155/2010/719696.
3.5. Gene Ontology Analysis. HTGM detected 18 changed
GO categories (FDR < 5%) enriched with diﬀerentially
expressed genes (Table 3). Processes related to enriched GO
categories included among others: macrophage activation,
response to wounding, response to virus, response to biotic
stimulus,interleukin-6biosyntheticprocess,I-kappaBkinase
NF-kappaB cascade, innate immune response, inﬂammatory
response, regulation of interleukin-6 biosynthetic process,
defenseresponse,positiveregulationofinterleukin-6biosyn-
theticprocess,activationofNF-kappaB-inducingkinase,and
interleukin-6 production. Evaluation of the clustered image
map indicates potential cross-talk among GO categories
enriched by advanced CAV genes. Instances of cross-talk are
of particular importance because they tie together categories
that, based on prior knowledge, might be thought of as
unrelated. A clustered heat map of diﬀerentially expressed
genes and enriched gene ontology categories and cross-talk
is shown in (Figure 2).
3.6. RT-PCR Validation. We compared the list of 291
candidate genes that we identiﬁed by SAM based on 5%
FDR for this exploratory study with the 252 candidate gene
list of the available RT-PCR generated in the Discovery
Phase of the CARGO study [18]. We found 8 transcripts
(7 diﬀerent genes) overlapping. The validation rate based
on Mann Whitney U-test comparison between absence of,
or mild CAV (n = 28) and advanced CAV (n = 5) was
75% (2 not validated out of 8). Validated genes included
FPRL1 (P = .005), S100A9 (P = .005), CXCL10 transcript
1( P = .009), and CXCL10 transcript 2 (P = .019), PRO1073
(P = .045), MMP9 (P = .045). Nonvalidated genes included
ENO1 (0.083) and FAS (P = .104). SAM-based diﬀerentially
expressed genes and the corresponding RT-PCR gene P-
values showed good concordance (Table 4).
4. Discussion
A gene signature is the group of genes in a type of cell
whosecombinedexpressionpatternisauniquecharacteristic6 Journal of Transplantation
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“Family with sequence similarity 26, member F”
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Early growth response 1
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Eukaryotic translation initiation factor 2-α kinase 2
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“Leukocyte immunoglobulin- like receptor, subfamily A (with TM domain), member 2”
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Figure 1: Clustered heat map of top 100 up- and down-regulated genes in patients with advanced transplant coronary artery disease and
controls. Gene symbol and gene name are provided when available. Platform unique identiﬁer is provided otherwise.Journal of Transplantation 7
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Table 3: Gene ontology categories enriched by genes expressed diﬀerentially between patients with and without advanced CAV.
Regulation in Adv-CAV Number of
genes GO category type Exemplary GO categories
Up-/Down-regulated 291 Biological process GO:0006955 immune response
GO:0002376 immune system process
GO:0051707 response to other organism
GO:0009607 response to biotic stimulus
GO:0006954 inﬂammatory response
GO:0050896 response to stimulus
GO:0009615 response to virus
GO:0009611 response to wounding
GO:0006952 defense response
GO:0045087 innate immune response
GO:0009605 response to external stimulus
GO:0042116 macrophage activation
GO:0006950 response to stress
Molecular function GO:0045408 regulation of interleukin-6 biosynthetic
process
GO:0007249 I-kappaB kinase NF-kappaB cascade
GO:0007243 protein kinase cascade
GO:0007009 plasma membrane organization and
biogenesis
GO:0032635 interleukin-6 production
GO:0042226 interleukin-6 biosynthetic process
GO:0045410 positive regulation of interleukin-6
biosynthetic process
GO:0009057 macromolecule catabolic process
GO:0009595 detection of biotic stimulus
GO:0007250 activation of NF-kappaB-inducing kinase
Up-Regulated 170 Biological process None
Molecular function None
Down-Regulated 123 Biological process GO:0006955 immune response
GO:0002376 immune system process
GO:0051707 response to other organism
GO:0009607 response to biotic stimulus
GO:0006954 inﬂammatory response
GO:0050896 response to stimulus
GO:0009615 response to virus
GO:0009611 response to wounding
GO:0006952 defense response
GO:0045087 innate immune response
GO:0009605 response to external stimulus
GO:0042116 macrophage activation
GO:0006950 response to stress
GO:0048518 positive regulation of biological process
GO:0002250 adaptive immune response
Molecular function GO:0045408 regulation of interleukin-6 biosynthetic
process
GO:0007249 I-kappaB kinase NF-kappaB cascade
GO:0007243 protein kinase cascade10 Journal of Transplantation
Table 3: Continued.
Regulation in Adv-CAV Number of
genes GO category type Exemplary GO categories
GO:0007009 plasma membrane organization and
biogenesis
GO:0032635 interleukin-6 production
GO:0042226 interleukin-6 biosynthetic process
GO:0045410 positive regulation of interleukin-6
biosynthetic process
GO:0009057 macromolecule catabolic process
GO:0009595 detection of biotic stimulus
GO:0007250 activation of NF-kappaB-inducing kinase
GO:0045084 positive regulation of interleukin-12
biosynthetic process
Adv-CAV: advanced cardiac allograft vasculopathy.
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Figure 2: Clustered heat map of enriched GO categories by diﬀerentially expressed genes. Instances of cross-talk are shown that links GO
categories enriched by similar genes. The green areas show GO categories enriched by the down-regulated genes while small red areas in the
corners show GO categories enriched by up-regulated genes.
Table 4: PCR corroboration of diﬀerentially expressed genes and
Microarray-based FDR.
Gene Up/Down FC P-value (PCR) FDR (Microarray)
FPRL1 up 2.3 .005 3
S100A9 up 2.9 .005 3.06
CXCL10b up 3.4 .009 1.41
CXCL10a up 3.4 .019 1.41
PRO1073 down 0.5 .045 2.35
MMP9 up 8.0 .045 3.13
ENO1 up 1.7 .083 4.60
FAS up 1.8 .104 4.17
of a disease under investigation. These disease speciﬁc gene
signatures can be used to select patients at a speciﬁc state
of a disease with an accuracy that facilitates the diagnosis of
the disease and selection of patients for diﬀerent treatment
options.
In this pilot study, patients with advanced CAV show
peripheral blood gene expression proﬁles that diﬀer already
in the early period after transplantation from those of
patients who will not develop advanced CAV. The ﬁndings
are consistent with previous suggestions that donor- and
recipient-related factors in the perioperative period may play
major roles in the immune response and development of
a sustained chronic response to immune injury, leading to
proliferation of the endovascular matrix, with consequent
obstruction of the blood ﬂow and impairment of allograft
function [2, 4, 9, 10].
In previous studies, gene expression proﬁles of PBMC
have been shown to correlate with presence or absence
of concurrent acute cellular rejection [16–18, 24], antibody
mediated rejection [19], and in response to mechanical
circulatory support device implantation [25, 26]. Based
on these gene expression proﬁles, the genomic classiﬁer
developedtoruleoutacutecellularcardiacallograftrejection
has also been shown to correlate with diﬀerent organ
function related parameters of rejection [27, 28], andJournal of Transplantation 11
longitudinal changes in clinical proﬁles [29, 30]. In current
study, we hypothesized that gene signatures early after HTx
correlate with future development of CAV. To the best of our
knowledge, this is the ﬁrst report of using a high throughput
genomic screening approach to identify patients at risk of
developing advanced CAV on the basis of leukocyte samples
obtained during the early period after transplantation. This
observation has potentially important implications.
Recently CAV has been reported as one of the major
causes of new-onset graft dysfunction and associated out-
comes [31]. Early detection of CAV was proposed as the
key strategy, to identify surrogate markers for late cardiac
allograft outcomes [1]. Currently, the most accurate diag-
nostic test to deﬁne the phenotype of CAV is intravascular
ultrasound [9]. Evaluation of the neointimal proliferation
rate between months 3 and 12 has been shown to predict
survival and major adverse cardiac events at long-term
follow-up [11] but intravascular ultrasound is invasive,
expensive and complication prone. Therefore, early proﬁling
of an immune response that diﬀerentiates a “high CAV-
risk phenotype” from a “low CAV-risk phenotype” may
become valuable to early identify these patients, model
timely therapeutic interventions and monitor response.
This concept in HTx is not new. Earlier observations in
animalmodelsofrejectionsuggestedthat“unstabletolerance
induction” is associated with the persistent immune activa-
tionthatmediatesdestructionofgraftparenchymalcells,and
that the evaluation of biological processes involved might
be useful in identifying diﬀerent types of rejection and the
likelihood of progression to chronic forms [32].
In our study, we found diﬀerentially expressed genes that
signiﬁcantly enriched GO categories including the innate
immunity, macrophage activation, interleukin-6, activation
oftheNF-KappaBcascadeandresponsetovirus.Theﬁnding
that the innate immune response plays an important role
is interesting because it has been already described in the
literature. Diﬀerentially expressed genes, among others in
this category, included Toll-like receptors 1, 4 and 6, and
Interleukin-23alpha.Severalauthorsproposedanimportant
role of innate immunity in the pathogenesis of CAV [10, 33–
35]. For example, it has been shown that in patients with
allograft endothelial dysfunction (an early clinical indicator
of transplant vasculopathy), mRNA transcript level and
surface expression of TLR-4 on circulating monocyte is sig-
niﬁcantly higher than controls [34]. According to our results
the categories related to these mechanisms were enriched
by the down-regulated genes. The interaction between the
up- and down-regulated genes collectively determines the
functioning of diﬀerent biological processes as assessed by
high through-put microarray analysis. Our observations
show some interesting expression patterns of these mecha-
nisms during the early period post-HTx which needs fur-
ther understanding. Therapy with Simvastatin that inhibits
allograft inﬂammatory activity and attenuates endothelial
coronary dysfunction shows reduced trans-cardiac IL-6 and
TNF-alpha gradients [33] and polymorphisms within the
promoter region of the IL-6 gene has been proposed as risk
markers for CAV [36]. In addition, the transcription factor
NFKB becomes up-regulated in response to CD40/ CD40
ligand mediating apoptosis of endothelial cells. Inhibition
of this pathway has been shown to be protective against
the development of CAV [37]. The GO analysis shows that
the STAT1 gene involved in the NFKB pathway is also part
of the response to virus showing a “cross-talk” between
both categories and suggesting that mechanisms of immune
damage related to viruses (i.e., CMV) [9, 10] may be related
to the NFKB pathway.
The ﬁndings presented in this paper should encourage
the development of strategies to advance evaluation and
management of heart transplant recipients in a preventative,
preemptive and personalized way, but the conclusion from
this pilot study should be interpreted within the important
limitations imposed by the small sample size, the use of
angiography which is an imperfect standard for detection
of CAV, and the known variable reproducibility of gene
expression studies [38]. Corroboration of genes was based
on retrospective PCR data. Only a small number of genes
were available that were present in the Microarray-based
candidate gene list.
In conclusion, our data show that peripheral blood
leukocyte genes, speciﬁcally innate immune response genes,
are diﬀerentially expressed during the early time after HTx
in patients who develop advanced CAV. Larger prospectively
designed studies are needed to corroborate our ﬁndings.
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